Platform
CIS BIOPHARMA has developed world-class capabilities for creating targeted cancer therapies, leveraging our expertise in protein engineering, linker chemistry, and bioconjugation of potent cancer drugs in our high containment laboratory. These core competencies form the three pillars of our platform.
Antibody-drug conjugates, ADCs - approved industry technologies
approved targets
0
including CD19, CD22, CD30, CD33, CD79b, HER2, Trop2, Nectin4, Tissue Factor, BCMA, and FRα.
approved payloads
0
including PBD, calicheamicin, DM1, DM4, MMAE, MMAF, Dxd, SN-38 and ETA.
approved linkers
0
including valine-citrulline, valine-alanine, tetrapeptide, CL2A, hydrazone, sulfo-SPDB and thioether.
Targeting Moieties
The first pillar of our platform harnesses the power of high-affinity antibodies and nanobodies designed to bind specific tumor-associated antigens, such as CD 171, L1CAM and CD 276, B7H3.
1. Antibodies are large, Y-shaped proteins that exhibit outstanding specificity and high affinity for antigens expressed on cancer cell surfaces. The precision optimizes their efficacy while sparing healthy tissues.
2. Nanobodies are smaller, single-domain antibody fragments that penetrate tumors more effectively. They accumulate rapidly in target tissues, offering unique advantages in the treatment of solid tumors and brain tumors.
Linker Technology
The second pillar of our platform comprises advanced linker and conjugation technology that ensures stable attachment of cytotoxic payloads to the targeting moieties.
1. Validated and novel linker chemistries: Incorporation of validated and novel linker designs, engineered for stability in blood and targeted release of payloads.
2. Dual-drug and high-DAR linker technology: Proprietary linker technology to attach a high number of drugs or two different drugs to targeting moieties.
3. Site-specific enzymatic conjugation: Precise attachment of payloads to specific sites on antibodies or nanobodies.
Payloads
The third pillar of our platform comprises a diverse arsenal of payloads to effectively eliminate cancer cells.
1. Topoisomerase-I-Inhibitors: Disrupt DNA replication, causing cellular damage and death.
2. Microtubule Inhibitors, MMAE: Potent agents that disrupt cancer cell division and induce apoptosis.
3. Radionuclides: Deliver targeted radiation to cancer cells inducing DNA damage.
